Clinical Trial Update: Combination of Alemtuzumab and Rituximab at Low-doses in Refractory Chronic Graft-Versus-Host Disease [NA]

View source ↗

Summary

A completed clinical trial evaluating low-dose alemtuzumab with rituximab for refractory chronic graft-versus-host disease, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Alemtuzumab (Alemtuzumab)
• Rituximab (rituximab)

Snippet

Sponsor: Hospital Universitario Dr. Jose E. Gonzalez | Conditions: Graft vs Host Disease | NA | Status: COMPLETED | Results posted: 2017-02-01